Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-07-02 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
第七届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on proposals related to stock price stabilization and share repurchase plans. The document does not contain financial statements or detailed financial data but rather the outcomes of board-level decisions and approvals. It is not an annual report, earnings release, or financial supplement. It is also not a general shareholder meeting announcement but a board/management information disclosure about internal decisions. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and focused on meeting resolutions, supporting this classification with high confidence.
2024-07-02 Chinese
竞价回购股份方案公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a share repurchase plan by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specifics about the repurchase purpose, scale, price range, funding source, implementation period, risk warnings, and board authorizations. The text explicitly discusses the company's plan to buy back its own shares, the financial impact, and regulatory compliance. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a brief announcement of a report publication but a substantive disclosure about share repurchase activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2024-07-02 Chinese
第六届董事会第二十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 27th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results on a specific proposal regarding the sale of a subsidiary's equity. The document is short (849 characters) and focuses on board meeting decisions rather than financial data or detailed reports. It does not contain financial statements, audit information, or regulatory certifications. It is not a full annual or interim report, nor an earnings release or investor presentation. It is clearly a Board/Management Information announcement about board meeting resolutions and decisions. Therefore, the appropriate classification is MANG (Board/Management Information).
2024-06-27 Chinese
出售资产的公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the sale of a 60% equity stake in a subsidiary company, including transaction overview, pricing, legal considerations, and board resolutions. It explicitly states that the transaction does not constitute a major asset restructuring and is not a related party transaction. The document includes financial data about the subsidiary and the parent company, details of the transaction agreement, and risk disclosures. This type of document is a capital or financing update related to asset sales and equity transfers, not a full financial report or earnings release. It is not a regulatory filing or announcement of a report publication but a substantive transaction announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-06-27 Chinese
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the implementation of the 2023 annual equity distribution (dividend) plan by Beijing Xinghao Pharmaceutical Co., Ltd. It details the dividend amount, the basis for distribution, tax implications, record dates, and payment methods. It references the shareholders' meeting approval and provides specific dividend payment information. The document is relatively short (2770 characters) and focuses on dividend distribution details rather than presenting full financial statements or comprehensive annual report content. Therefore, it fits the category of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release.
2024-06-17 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a disclosure announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management by purchasing financial products. It details the amounts, types, counterparties, and risk controls related to the entrusted financial management of idle raised funds. The document is an update on financing activities related to the use of raised capital, not a full financial report or earnings release. It does not contain comprehensive financial statements or management analysis but focuses on capital usage and investment activities. The document length is 3870 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-06-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.